Home The Word Brain	My Amedeo FAQ Privacy About
	C49 + CC Journal Club For more information, please refer to our special emails from April 13 and May 19.

Ophthalmology

Free Subscription Articles published in Lancet Retrieve available abstracts of 27 articles: HTML format

Single Articles

March 2025
1. KIRTANE AJ, Genereux P, Lewis B, Shlofmitz RA, et al
   Orbital atherectomy versus balloon angioplasty before drug-eluting stent implantation in severely calcified lesions eligible for both treatment strategies (ECLIPSE): a multicentre, open-label, randomised trial.
   Lancet. 2025 Mar 28:S0140-6736(25)00450-7. doi: 10.1016/S0140-6736(25)00450.
   PubMed     Abstract available
   
   
   
2. COUGHLAN JJ, Byrne RA
   Orbital atherectomy for severely calcified coronary artery lesions.
   Lancet. 2025 Mar 28:S0140-6736(25)00572-0. doi: 10.1016/S0140-6736(25)00572.
   PubMed    
   
   
   February 2025
3. MICHAELIDES M, Laich Y, Wong SC, Oluonye N, et al
   Gene therapy in children with AIPL1-associated severe retinal dystrophy: an open-label, first-in-human interventional study.
   Lancet. 2025;405:648-657.
   PubMed     Abstract available
   
   
   January 2025
4. ACHARYA NR, Ramanan AV, Coyne AB, Dudum KL, et al
   Stopping of adalimumab in juvenile idiopathic arthritis-associated uveitis (ADJUST): a multicentre, double-masked, randomised controlled trial.
   Lancet. 2025;405:303-313.
   PubMed     Abstract available
   
   
   
5. FOELL D, Heiligenhaus A
   Uveitis in juvenile idiopathic arthritis: when to stop adalimumab?
   Lancet. 2025;405:274-276.
   PubMed    
   
   
   November 2024
6. SOMA T, Oie Y, Takayanagi H, Matsubara S, et al
   Induced pluripotent stem-cell-derived corneal epithelium for transplant surgery: a single-arm, open-label, first-in-human interventional study in Japan.
   Lancet. 2024 Nov 7:S0140-6736(24)01764-1. doi: 10.1016/S0140-6736(24)01764.
   PubMed     Abstract available
   
   
   
7. HIRAMI Y, Mandai M
   Opening the door to widespread iPSC-derived regenerative therapy for corneal epithelial opacity.
   Lancet. 2024 Nov 7:S0140-6736(24)01965-2. doi: 10.1016/S0140-6736(24)01965.
   PubMed    
   
   
   September 2024
8. YANG P, Pardon LP, Ho AC, Lauer AK, et al
   Safety and efficacy of ATSN-101 in patients with Leber congenital amaurosis caused by biallelic mutations in GUCY2D: a phase 1/2, multicentre, open-label, unilateral dose escalation study.
   Lancet. 2024;404:962-970.
   PubMed     Abstract available
   
   
   
9. MACLAREN RE
   Gene therapy in the early stages of retinal degeneration.
   Lancet. 2024;404:911-913.
   PubMed    
   
   
   August 2024
10. HONG SJ, Lee SJ, Lee SH, Lee JY, et al
    Optical coherence tomography-guided versus angiography-guided percutaneous coronary intervention for patients with complex lesions (OCCUPI): an investigator-initiated, multicentre, randomised, open-label, superiority trial in South Korea.
    Lancet. 2024 Aug 30:S0140-6736(24)01454-5. doi: 10.1016/S0140-6736(24)01454.
    PubMed     Abstract available
    
    
    
11. MAMAS MA, Mintz GS
    Optical coherence tomography imaging for complex percutaneous coronary intervention.
    Lancet. 2024 Aug 30:S0140-6736(24)01593-9. doi: 10.1016/S0140-6736(24)01593.
    PubMed    
    
    
    
12. FISHER BA, Mariette X, Papas A, Grader-Beck T, et al
    Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjogren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study.
    Lancet. 2024;404:540-553.
    PubMed     Abstract available
    
    
    
13. COLAFRANCESCO S, Priori R
    Sjogren's disease: a new era for clinical trials?
    Lancet. 2024;404:498-499.
    PubMed    
    
    
    July 2024
14. PATEL JN, Miller NR
    Non-arteritic anterior ischaemic optic neuropathy causes sudden-onset painless loss of vision.
    Lancet. 2024;404:67.
    PubMed    
    
    
    June 2024
15. YING GS, VanderBeek BL
    Radiotherapy for anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration.
    Lancet. 2024 Jun 11:S0140-6736(24)00915-2. doi: 10.1016/S0140-6736(24)00915.
    PubMed    
    
    
    
16. JACKSON TL, Desai R, Wafa HA, Wang Y, et al
    Stereotactic radiotherapy for neovascular age-related macular degeneration (STAR): a pivotal, randomised, double-masked, sham-controlled device trial.
    Lancet. 2024 Jun 11:S0140-6736(24)00687-1. doi: 10.1016/S0140-6736(24)00687.
    PubMed     Abstract available
    
    
    May 2024
17. PROUDLOCK FA, Hisaund M, Maconachie G, Papageorgiou E, et al
    Extended optical treatment versus early patching with an intensive patching regimen in children with amblyopia in Europe (EuPatch): a multicentre, randomised controlled trial.
    Lancet. 2024;403:1766-1778.
    PubMed     Abstract available
    
    
    
18. ZHOU S, Zhou J
    New advances in amblyopia therapy: early patching is more effective than extended optical treatment.
    Lancet. 2024;403:1725-1727.
    PubMed    
    
    
    April 2024
19. WILENIUS M, Jernman J, Hietaharju A, Salonen T, et al
    Swollen eyelids caused by polyvinylpyrrolidone histiocytosis with intravenous methylphenidate.
    Lancet. 2024;403:1574-1575.
    PubMed    
    
    
    March 2024
20. CAMPOCHIARO PA, Avery R, Brown DM, Heier JS, et al
    Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study.
    Lancet. 2024 Mar 27:S0140-6736(24)00310-6. doi: 10.1016/S0140-6736(24)00310.
    PubMed     Abstract available
    
    
    
21. RAKOCZY EP
    The promise of long-term treatment for neovascular age-related macular degeneration.
    Lancet. 2024 Mar 27:S0140-6736(24)00428-8. doi: 10.1016/S0140-6736(24)00428.
    PubMed    
    
    
    
22. EMMI G, Bettiol A, Hatemi G, Prisco D, et al
    Behcet's syndrome.
    Lancet. 2024;403:1093-1108.
    PubMed     Abstract available
    
    
    
23. BROWN DM, Boyer DS, Do DV, Wykoff CC, et al
    Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial.
    Lancet. 2024 Mar 7:S0140-6736(23)02577-1. doi: 10.1016/S0140-6736(23)02577.
    PubMed     Abstract available
    
    
    
24. LANZETTA P, Korobelnik JF, Heier JS, Leal S, et al
    Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial.
    Lancet. 2024 Mar 7:S0140-6736(24)00063-1. doi: 10.1016/S0140-6736(24)00063.
    PubMed     Abstract available
    
    
    
25. CHEW EY
    Increasing concentrations of intravitreal therapies for neovascular age-related macular degeneration.
    Lancet. 2024 Mar 7:S0140-6736(24)00229-0. doi: 10.1016/S0140-6736(24)00229.
    PubMed    
    
    
    
26. GABRIELLE PH, Creuzot-Garcher C
    Can high-dose aflibercept satisfy unmet treatment needs in diabetic macular oedema?
    Lancet. 2024 Mar 7:S0140-6736(23)02760-5. doi: 10.1016/S0140-6736(23)02760.
    PubMed    
    
    
    October 2023
27. KHANANI AM, Patel SS, Staurenghi G, Tadayoni R, et al
    Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial.
    Lancet. 2023;402:1449-1458.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ophthalmology is free of charge.